Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

Back to Item »

Aestus Gains Rights to Prosidion’s Neuropathic Pain Drug and Expands Collaboration with ALS TDI

In deal with Prosidion, firm will initially carry out Phase II development of glycogen phosphorylase inhibitor.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »